PEPTIDES
$119.00
⚠️ For Research Use Only — This product is not intended for human consumption. By purchasing, you confirm you are a qualified researcher.
CJC-1295 (No DAC) is a modified growth hormone-releasing hormone analog engineered with amino acid substitutions that confer resistance to dipeptidyl peptidase-IV (DPP-IV) enzymatic degradation. This research peptide binds to the GHRH receptor on pituitary somatotroph cells, providing a sustained stimulus for studying GH axis dynamics with extended signaling duration compared to native GHRH fragments.
CJC-1295 without Drug Affinity Complex (No DAC) is a 30-amino acid synthetic analog of GHRH(1-29) with four amino acid substitutions at positions 2, 8, 15, and 27. These modifications were specifically engineered to protect the peptide from cleavage by DPP-IV, a serine exopeptidase that rapidly degrades native GHRH in circulation. The result is a research peptide with an extended functional half-life that maintains full agonist activity at the GHRH receptor. Like endogenous GHRH, CJC-1295 (No DAC) activates the Gs-coupled GHRH receptor, stimulating adenylyl cyclase, cAMP production, and downstream PKA activation in somatotroph cells. Published studies have shown that CJC-1295 analogs produce sustained elevations in GH and IGF-1 levels in preclinical models compared to unmodified GHRH fragments (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). Researchers use this peptide to study prolonged GH axis stimulation, the pharmacokinetic impact of DPP-IV resistance, and the downstream metabolic effects of sustained GH elevation.
CJC-1295 (No DAC) binds the GHRH receptor with comparable affinity to native GHRH(1-29), activating the Gs/adenylyl cyclase/cAMP/PKA cascade. The key mechanistic distinction lies in its DPP-IV resistance: substitutions at Ala2, Gln8, Ala15, and Leu27 prevent the N-terminal cleavage that normally inactivates GHRH within minutes. This results in prolonged receptor stimulation and sustained cAMP signaling in somatotroph cells. Downstream, PKA-mediated CREB phosphorylation drives GH gene transcription, while calcium channel activation promotes GH vesicle release. Research has demonstrated that the extended signaling window amplifies total GH output per pulse without disrupting the underlying pulsatile secretion pattern, making this peptide valuable for studying dose-duration relationships in GH axis pharmacology.
Unlike Sermorelin, which closely mimics the native GHRH(1-29) sequence with a short half-life, CJC-1295 (No DAC) incorporates DPP-IV-resistant substitutions for extended activity. Tesamorelin is another GHRH analog but retains the full 44-amino acid sequence with a trans-3-hexenoic acid modification. Researchers select among these analogs based on whether their experimental design requires acute, sustained, or structurally distinct GHRH receptor stimulation.
Related products in the Axiom Research Supply catalog: Sermorelin, Ipamorelin, Tesamorelin.
Reconstitute in bacteriostatic water or sterile saline. Store reconstituted peptide at 2–8°C and use within 30 days. Lyophilized powder should be stored at -20°C. Avoid repeated freeze-thaw cycles.
Axiom Research Supply provides CJC-1295 (No DAC) at ≥98% (HPLC verified), verified through independent HPLC analysis with third-party testing documentation. Every batch undergoes rigorous quality control including identity confirmation, purity assessment, and endotoxin testing. Our peptides are properly lyophilized and shipped with cold-chain protocols to maintain stability from production to your laboratory. Axiom Research Supply is committed to advancing metabolic peptide science with precision, reproducibility, and dedicated research support. Access our educational resources including the Axiom Research Supply Metabolic Peptide Research eBook for comprehensive scientific background.
| Product Name | CJC-1295 (No DAC) |
| Available Sizes | Multiple dosage options available — see product listing |
| CAS Number | 863288-34-0 |
| Molecular Formula | C152H252N44O42 |
| Molecular Weight | 3367.97 g/mol |
| Purity | ≥98% (HPLC verified) |
| Physical Form | Lyophilized Powder |
| Storage | Store at -20°C, protect from light and moisture |
| Peptide Class | Modified GHRH Analog (DPP-IV Resistant) |
| Key Receptor Targets | GHRH Receptor (GHRH-R) |
| Research Applications | GHRH receptor signaling, sustained GH axis stimulation, DPP-IV resistance studies, somatotroph cell models |
wpadmin –
Working at Sam.AI has been an incredible journey so far. The technology we’re building is truly cutting-edge, and being a part of a team that’s revolutionizing how people achieve their goals is immensely fulfilling.